Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebdarokimab - Akeso Biopharma

Next Previous
Drug Profile

Ebdarokimab - Akeso Biopharma

Alternative Names: AK-101

Latest Information Update: 25 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Plaque psoriasis
  • Phase I Ulcerative colitis
  • Preclinical Systemic lupus erythematosus
  • No development reported Crohn's disease; Psoriatic arthritis

Most Recent Events

  • 18 Apr 2025 Registered for Plaque psoriasis in China (SC)
  • 23 Jan 2024 Ebdarokimab is still in phase I trial for Ulcerative colitis in USA and China (SC) (Akeso Biopharma pipeline, January 2024)
  • 23 Jan 2024 Akeso Biopharma completes a phase I trial in Ulcerative colitis in USA and China (SC) prior to January 2024 (Akeso Biopharma pipeline, January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top